Michelle Tindall, a research practitioner involved in the project, said: "Cancer affects so many people, of all ages, directly or indirectly. The breath test works by detecting volatile organic compounds present in a person’s breath. Research has shown that people with cancer produce a different combination of these compounds compared to those without the disease. The Vapor2 study is focused on pancreatic cancer and is funded by the charity Pancreatic Cancer UK. The Panacea study is expected to continue until December 2026, while the VAPOR2 study will run until 2028.